New oral GLP-1 drug delivers up to 12% weight loss in 36 weeks. A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to a 12% reduction in body weight after 36 weeks, according to a randomized phase II clinical trial published in Nature Medicine.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to a 12% reduction in body weight after 36 weeks, according to a randomized phase II clinical trial published in Nature Medicine.
- Ponto de atenção: oral.
- Ponto de atenção: drug.
- Ponto de atenção: delivers.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
:quality(85)/f6af3fc0-483e-4190-98f8-f6fc36168b7c.png)